Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494034 | 0.86 | PRKDC (0.53) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL4067830 | 0.80 | ALDH1A1 (0.64) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL29655238 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL1539323 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL1494390 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL18430735 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL7281047 | 0.79 | CYP1A2 (0.46) | PRKDCGAA | |
| SCHEMBL1493885 | 0.78 | ALDH1A1 (0.61) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| Ammonia Solution, Strong SCHEMBL27836692 | 0.77 | CYP1A2 (0.45) | PRKDCGAA | |
| SCHEMBL18712666 | 0.77 | P2RX3 (0.48) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals, Inc. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4215182-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215182-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-3355889-B1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | AFFERENT PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220143015-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3981406-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | Afferent Pharmaceuticals Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-7858632-B2 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1924264-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025925-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025925-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| EP-1725540-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095359-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | ALDH1A1 2017/4885KDM4E 3345/4885TSHR 1029/4885 |
| US-20220143015-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | P2RX3, P2RX2, P2RX5 | ALDH1A1 1122/4885KDM4E 4640/4885TSHR 1021/4885 |
| US-20050209260-A1 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | P2RX3, P2RX2, P2RX1 | ALDH1A1 2010/4885KDM4E 2921/4885TSHR 1157/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | ALDH1A1 2017/4885KDM4E 3345/4885TSHR 1029/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | ALDH1A1 2230/4885KDM4E 3901/4885TSHR 533/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | ALDH1A1 2017/4885KDM4E 3345/4885TSHR 1029/4885 |
| US-20070049609-A1 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | P2RX3, P2RX2, P2RX1 | ALDH1A1 2230/4885KDM4E 3901/4885TSHR 533/4885 |
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | P2RX3, P2RX2, P2RX5 | ALDH1A1 1122/4885KDM4E 4640/4885TSHR 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.